Christopher Baltes, MD
Family Medicine · Fort Wayne, INNPI 1992090971
Payments from drug & device makers
Across 76 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$268
- Pfizer$126
- AstraZeneca$124
- Lilly USA, LLC$114
- AbbVie$107
- GSK$70
- plus $394 from 13 others
What the payments were for
- Food & beverage$1,18899%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $268 |
| Pfizer | 8 | $126 |
| AstraZeneca | 7 | $124 |
| Lilly USA, LLC | 7 | $114 |
| AbbVie | 7 | $107 |
| GSK | 5 | $70 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Johnson & Johnson | 4 | $59 |
| Boehringer Ingelheim | 3 | $46 |
| Amgen | 3 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Bayer | 2 | $30 |
| Exact Sciences | 2 | $29 |
| Abbott | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Merck | 1 | $11 |
How this compares
$1,203 in reported general payments places this provider in the 60th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 436 | $164,847 |
| JardianceEmpagliflozin | 129 | $108,041 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 56 | $56,367 |
| JanuviaSitagliptin Phosphate | 108 | $48,441 |
| XareltoRivaroxaban | 131 | $43,055 |
| FarxigaDapagliflozin Propanediol | 78 | $40,208 |
| GemtesaVibegron | 155 | $36,483 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $35,384 |
| OzempicSemaglutide | 26 | $28,296 |
| MyrbetriqMirabegron | 94 | $22,058 |
| MounjaroTirzepatide | 20 | $21,356 |
| TrulicityDulaglutide | 43 | $19,231 |
| TradjentaLinagliptin | 54 | $16,614 |
| NamzaricMemantine Hcl/Donepezil Hcl | 87 | $13,136 |
| LinzessLinaclotide | 12 | $11,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $164,847436 claims |
| Boehringer IngelheimJardiance, Tradjenta | $46 | $124,654183 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $34 | $59,99798 claims |
| MerckJanuvia, Janumet Xr | $11 | $59,562119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $124 | $55,237110 claims |
| Johnson & JohnsonXarelto | $59 | $43,055131 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $70 | $41,21944 claims |
| Lilly USA, LLCMounjaro, Trulicity | $114 | $40,58763 claims |
| Novo NordiskOzempic | $268 | $28,29626 claims |
| AbbVieNamzaric, Linzess | $107 | $24,91899 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.